Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02264613 · OUTCOME

Determine the Maximum Tolerated Dose (MTD) of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas · Source last updated 2026-01-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
mg/kg
Interval / dispersion
Not reported
Time frame
From Day 1 of treatment until 30 days after the last cycle of treatment (each cycle in DR-A is 28 days, DR-B and DR-C is 21 days), an average of 138 Days

What was measured

Determine the maximum tolerated dose (MTD)

Groups in this outcome

Dose Regimen A (DR-A) Escalation

Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle. ALRN-6924: ALRN-6924 will be administered as an IV infusion

Dose Regimen B (DR-B) Escalation

Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle ALRN-6924: ALRN-6924 will be administered as an IV infusion

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Regimen A (DR-A) Escalation41
Dose Regimen B (DR-B) Escalation30

Reported measurements

Source class 1
Values in mg/kg · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dose Regimen A (DR-A) Escalation3.1Not reportedNot reportedNot reportedNot reported
Dose Regimen B (DR-B) EscalationNANot reportedNot reportedNot reportedNo MTD found
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3.1
      2. comment
        No MTD found
        group Id
        OG001
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      41
    2. group Id
      OG001
      value
      30
    units
    Participants
description
Determine the maximum tolerated dose (MTD)
groups
  1. description
    Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 8 and 15 of a 28-day cycle. ALRN-6924: ALRN-6924 will be administered as an IV infusion
    id
    OG000
    title
    Dose Regimen A (DR-A) Escalation
  2. description
    Drug: ALRN-6924 Weight-based-dosing administered IV on days 1, 4, 8 and 11 of a 21-day cycle ALRN-6924: ALRN-6924 will be administered as an IV infusion
    id
    OG001
    title
    Dose Regimen B (DR-B) Escalation
param Type
NUMBER
reporting Status
POSTED
time Frame
From Day 1 of treatment until 30 days after the last cycle of treatment (each cycle in DR-A is 28 days, DR-B and DR-C is 21 days), an average of 138 Days
title
Determine the Maximum Tolerated Dose (MTD) of ALRN-6924 in Adult Patients With Advanced Solid Tumors or Lymphomas
type
PRIMARY
unit Of Measure
mg/kg

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice